DKSH is pleased to announce a strategic partnership with GentleGen, a biotechnology company specializing in automated solutions for gene synthesis, Oligo synthesis, Sanger sequencing, gene editing, and protein expression in Thailand
Bangkok, Thailand, Aprilย 21, 2025 โ DKSH Business Unit Technology partners with GentleGen to enhance scientific instrumentation services in Thailand, offering a one-stop solution with sales, marketing, and application support. With a skilled team and a structured market approach, DKSH expands beyond traditional distributors, providing full technical support and fostering strong partnerships.
ย
This collaboration complements DKSHโs existing portfolio of scientific solutions services while expanding into new market segments. Leveraging its expertise and industry connections, DKSH strengthens customer engagement and drives growth in Thailandโs scientific instrumentation sector.
ย
Frank Sun, CEO of GentleGen, stated: โWe are excited to partner with DKSH Thailand, a leader in scientific instrumentation and market expansion services. This collaboration aligns with our mission to revolutionize life science engineering through AI-driven biotechnology and automation. By combining GentleGenโs innovative one-stop gene service platform with DKSHโs extensive market expertise, we aim to deliver cutting-edge solutions that accelerate R&D and meet the growing demands of Thailandโs life sciences sector. Together, we are committed to driving progress in synthetic biology and improving lives through advanced technologies.โ
ย
Mr. Kongsak Ermukdakul, Managing Director, Business Unit Technology, DKSH Thailand, shared: โWe are thrilled to work with GentleGen, as it perfectly aligns with our vision of advancing the life sciences sector. As a pioneer in oligo synthesis, sanger sequencing, gene synthesis, and protein antibody, this strategic partnership will not only strengthen our presence in Thailand but also enhance our ability to offer cutting-edge solutions to meet the growing needs of the scientific solutions market. By incorporating this innovative brand, we continue to build on our commitment to delivering high-quality products that drive progress and improve lives.โ
ย
About GentleGen
Founded in 2021, GentleGen is dedicated to advancing life science engineering through AI-driven biotechnology and automation. It has developed an intelligent one-stop gene service platform for gene synthesis, oligonucleotide synthesis, Sanger sequencing, high-throughput sequencing, gene editing, and protein expression, accelerating life sciences R&D and driving progress in synthetic biology. In addition, GentleGen has established a comprehensive biopharmaceutical safety evaluation system, ensuring the safety of nucleic acid drugs, gene therapies, gene editing drugs, and protein drugs from early R&D to clinical stages. With an intelligent production workshop and a strong focus on innovation, the company is committed to contributing to global health and sustainable development. https://en.gentlegen.com/about
ย
About DKSH
For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching peopleโs lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Technology offers complete solutions for specialized scientific and industrial applications. With around 1,820 specialists, the Business Unit generated net sales of CHF 549 million in 2024. www.dksh.com/tec